Peter Blume-Jensen, Acrivon Therapeutics CEO
June 29, 2021 08:00 AM EDTUpdated 10:31 AM
Startups
Deals

Can a small band of bio­phar­ma play­ers suc­ceed where Eli Lil­ly failed? They’re tak­ing a shot

John Carroll

Editor & Founder

Eli Lil­ly didn’t try to spin any­thing about the mid-stage da­ta they got on their CHK1/CHK2 drug prex­as­ert­ib for ovar­i­an can­cer pa­tients. The drug failed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times